Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Trial ID or NCT#
Status
Purpose
This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come back. Diagnostic procedures, such as gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 PET/MRI, may help find and diagnose prostate cancer and find out how far the disease has spread.
Official Title
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
Eligibility Criteria
- * Biopsy proven prostate adenocarcinoma.* Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).
- a. Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation.
- (i) PSA greater than 0.2 ng/mL measured after at least 6 weeks from radical prostatectomy.
- (ii) Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL).
- b. Post-radiation therapy ? American Society for Therapeutic Radiology and Oncology (ASTRO)-Phoenix consensus definition.
- (i) A rise of PSA measurement of 2 or more ng/mL over the nadir.
- * Able to provide written consent.* Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent).
- * Inability to lie still for the entire imaging time.* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.).* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.* Known allergy, hypersensitivity, or intolerance to the investigational product or its excipients.* Metallic implants (contraindicated for magnetic resonance imaging \[MRI\]).
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Andrei Iagaru
650-725-4711
View on